As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Carrion, Ricardo
Funded by
National Institutes of Health
Collaborating Institutions
BioCryst Pharmaceuticals
Inc
The overall goal is to evaluate the potential treatment efficacy of IV-dosed galidesivir.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Martinez-Sobrido, Luis
Collaborating Institutions
University of Texas Health Science Center San Antonio
Exploiting the Viral RNA Methylation Machinery for SARS-CoV-2 Therapy
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Hayhurst, Andrew
Funded by
National Institutes of Health
Unique proteins and peptides can transform salt solutions into crystals visible to the naked eye. The goal if this project is to couple these motifs to small antibodies that recognize repetitive components of pathogens so that the presence of a microbe will be signaled by the appearance of a crystal. This process could lead to the development of a new generation of inexpensive and easy to use point-of-care tests for diseases that will advance human healthcare.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Ebrahimi, Diako
Collaborating Institutions
University of Texas Health Science Center San Antonio
We aim to fully characterize mutational signatures of SARS-CoV-19 focusing on the furin cleavage site, determine the role of the GC-rich sequence and CpG sites within the furin cleavage site and develop neutralizing Abs to target the furin cleavage site.
The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Perry, George
Plascencia Villa, German
Funded by
Univ of TX HSC at Houston 744
Alzheimer's disease (AD) is increasing in number as the U.S. and global population gets older. Despite enormous effort and expense. treatment remains at best modestly effective and no new drugs have been approved since 2003 [1.2]. The increasing interest in drug discovery through repositioning old drugs for new therapeutic applications throw light in the treatment for neurodegenerative diseases including AD [3].
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Jonathan Bohmann
Funded by
Medical CBRN Defense Consortium
Collaborating Institutions
University of Pittsburgh
Defense Threat Reduction Agency
Medical CBRN Defense Consortium
Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.
BioBridge Global is a San Antonio, Texas-based nonprofit corporation that offers diverse services through its subsidiaries – the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure and the Blood & Tissue Center Foundation.
Funded by
MTEC grant
Collaborating Institutions
U.S. Army Institute of Surgical Research Coagulation and Blood Research,
StemBioSys,
RoosterBio
BioBridge Global has been named one of two Prototype of the Year Award winners by the Medical Technology Enterprise Consortium (MTEC) for work done following a $7.8 million MTEC grant for the development of large-scale manufacturing capabilities for clinical-grade adult stem cells.
The award was presented at the MTEC Annual Meeting on March 4.